ABBVIE INC. news, videos and press releases
For more news please use our advanced search feature.
ABBVIE INC. - More news...
ABBVIE INC. - More news...
- AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis
- AbbVie to Host First-Quarter 2025 Earnings Conference Call
- AbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025
- AbbVie to Present at the Leerink Partners Global Healthcare Conference
- AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
- AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis
- AbbVie to Present at the TD Cowen's 45th Annual Health Care Conference
- AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors
- AbbVie Declares Quarterly Dividend
- AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
- U.S. FDA Approves EMBLAVEO™ (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections With Limited or No Treatment Options
- Allergan Aesthetics Invites Consumers to Join the Faces of Natrelle® Campaign
- Allergan Aesthetics, the American Society of Plastic Surgeons (ASPS) and The Aesthetic Society Release Two New Engaging LIMITLESS Videos Celebrating Women Surgeons
- AbbVie Reports Full-Year and Fourth-Quarter 2024 Financial Results
- Allergan Aesthetics launches new AA Signature Program at IMCAS 2025 to redefine patient-centric, multimodal treatment plans
- AbbVie Completes Acquisition of Nimble Therapeutics
- AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology
- Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
- Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
- AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
- AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
- AbbVie to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- CoolMonth is Back With Deals on CoolSculpting® Elite by Allergan Aesthetics
- AbbVie to Host Full-Year and Fourth-Quarter 2024 Earnings Conference Call
- AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline
- AbbVie Completes Acquisition of Aliada Therapeutics
- Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma
- AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
- AbbVie Announces Emotional Impact Report on Mental Health of Underrepresented CLL Cancer Patients
- Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
